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Abstract Hepatocyte growth factor (HGF) inhibits acute liver
injury. NK2 acts as an antagonist to HGF in vitro, but its in
vivo function has reached no consensus conclusions. We have
investigated in vivo e¡ects of HGF and NK2 on CCl4-induced
acute liver injury. Elevation of the serum alanine aminotransfer-
ase level and extension of centrilobular necrosis were inhibited
in HGF transgenic mice but were promoted in NK2 transgenic
mice. Hepatocyte proliferation after liver injury was not inhib-
ited in NK2 transgenic mice. Thus, this study indicates that
HGF inhibits liver injury, and NK2 antagonizes HGF on liver
injury, however, NK2 may not antagonize HGF on hepatocyte
proliferation.
+ 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Hepatocyte growth factor (HGF) was puri¢ed from the
plasma of a patient with fulminant hepatic failure [1] and is
now known as a pleiotropic cytokine that stimulates mitogen-
esis, motogenesis, and morphogenesis [2]. The e¡ects of HGF
are mediated through the receptor, c-Met [3]. HGF reportedly
prevents acute hepatic injury caused by a variety of hepato-
toxins including carbon tetrachloride (CCl4) [4^10].
Structurally, HGF consists of an K-subunit of 60 kDa con-
taining an N domain and four kringle domains and a L-sub-
unit of 30 kDa [11]. Naturally, HGF mRNA can undergo
alternative splicing to create truncated isoforms, NK1 (con-
sisting of an N domain and the ¢rst kringle domain of HGF)
and NK2 (consisting of an N domain and the ¢rst two kringle
domains of HGF) [12,13]. These two isoforms can bind to
c-Met with relatively high a⁄nity and both were initially char-
acterized as an HGF antagonist [13^15]. However, the biolog-
ical activity of NK1 was later reported to stimulate mitogen-
esis, motogenesis, and morphogenesis [16,17]. On the other
hand, NK2 has been reported to act as an agonist of moto-
genic activity [18,19].
In HGF transgenic mice, using a mouse metallothionein
(MT)-1 promoter and associated locus control regions, HGF
overexpression led to stimulation of hepatic proliferation and
regeneration [20]. Recently, it was reported that NK1 trans-
genic mice showed phenotypes almost similar to those of
HGF transgenic mice [12]. In NK2 transgenic mice, using
the same expression construct as HGF and NK1 transgenic
mice, there were no overt phenotypic abnormalities. However,
in bitransgenic mice harboring both HGF and NK2 trans-
genes, NK2 overexpression inhibited phenotypic abnormal-
ities induced by overexpression of HGF, including liver en-
largement and accelerated hepatocyte proliferation [23]. In
contrast, when melanoma cells, which exhibited very high
c-Met expression and predominantly metastasized to the liver
[24], were introduced intravenously into the tail vein of NK2
transgenic mice, NK2 overexpression stimulated the meta-
static e⁄ciency of these cells [23]. These in vivo data indicate
that NK2 acts as an antagonist of HGF in mitogenesis but an
agonist of HGF in respect of metastatic activity.
To obtain more direct evidence of the preventive e¡ect of
HGF and to elucidate the role of NK2 in CCl4-induced acute
liver injury, we exploited HGF and NK2 transgenic mice [23].
2. Materials and methods
2.1. Animals
HGF and NK2 transgenic mice were generated on an albino FVB
genetic background as previously described [21,23]. Expressions of the
mouse HGF cDNA and the human NK2 cDNA were placed under
the control of the mouse MT-1 promoter and associated locus control
regions as previously [25]. All studies were performed using only fe-
male mice and mice were maintained in compliance with the guide-
lines for animal care and use established by Gunma University School
of Medicine.
2.2. Assessment of liver injury
Wild-type (WT) and transgenic mice were maintained on 25 mM
zinc sulfate (ZnSO4) in their drinking water, starting 4 weeks after
birth, to enhance transgene expressions. WT mice were littermates of
transgenic mice. Mice were injected intraperitoneally with 0.25 ml/kg
CCl4 (Kanto Chemistry, Tokyo, Japan) dissolved in olive oil (Kanto
Chemistry, Tokyo, Japan) at 6 weeks of age and were sacri¢ced, and
their sera and livers were collected at speci¢ed time points. Serum
alanine aminotransferase (ALT) levels were measured at each point,
and liver tissues were ¢xed in 10% formalin, embedded in para⁄n and
stained with hematoxylin^eosin. At a magni¢cation of U40, 30 areas
of centrilobular necrosis and the cross section of central vein in the
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necrosis were measured using a software, NIH Image 1.62, provided
by the National Institute of Health (MD, USA) for each group. Each
area is indicated by a Pixels number. The index of centrilobular ne-
crosis was scored as follows: the area of centrilobular necrosis divided
by the area of cross section of the central vein in the necrosis.
2.3. Northern blot analysis
Total RNAs from liver tissues were prepared using TRIzol (Gibco
BRL, Tokyo, Japan) according to the manufacturer’s instructions,
and 20 Wg of total RNA was loaded per lane onto a 1% agarose-
formaldehyde gel and transferred to a nylon membrane (Amersham
Pharmacia Biotech, Tokyo, Japan). Transcripts of transgenes and
endogeneous HGF were detected with a 2.2-kbp mouse HGF
cDNA probe as previously described [22]. Transcripts of c-met were
detected with a 1.5-kbp mouse c-met cDNA probe as previously de-
scribed [22]. MT transcripts were detected with a 355-bp mouse MT-1
cDNA probe (generously provided by Richard Palmiter, University of
Washington, Seattle, WA, USA). The membrane was rehybridized
with a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe,
and RNA levels of trangenes and endogeneous c-met and MT were
quanti¢ed by densitometric analysis related to GAPDH levels.
2.4. Immunohistochemistry
Liver tissues were removed on days 0 and 2 for proliferating cell
nuclear antigen (PCNA) staining using monoclonal mouse anti-PCNA
antibody (PC-10; Dako Japan, Tokyo, Japan). The labeled hepato-
cyte nuclei were scored by counting 30 high-power light microscope
¢elds (U1000) for each group.
2.5. Statistical analysis
All experimental data are shown as meansPS.D. Di¡erences in
serum ALT levels were determined by two-way factorial analysis of
variance (ANOVA) for each group. Di¡erences in the index of cen-
trilobular necrosis and PCNA-labeled hepatocytes were determined by
one-way ANOVA and the Fisher test as a post-hoc test for each
group. The level of signi¢cance for all statistical analyses was set at
P6 0.01.
3. Results
3.1. Liver injury after injection of CCl4
As shown in Fig. 1, serum ALT levels in NK2 transgenic
mice were approximately twice and three times as high as
those in WT mice on days 1 and 2, respectively. In contrast,
the serum ALT levels in HGF transgenic mice were much
lower than those in WT mice on days 1 and 2. Histological
examination revealed that CCl4 administration induced cen-
trilobular necrosis with ballooning degeneration of hepato-
cytes on day 2 in the WT mice (Fig. 2A,B). The extent of
liver injury in the NK2 transgenic liver was larger than that in
WT mice (Fig. 2C,D). The indices of centrilobular necrosis in
NK2 transgenic mice and WT mice were 30.1 P 16.2 and
25.2P 9.60, respectively (P=0.10). In contrast, the hepatic
damage was much less severe in HGF transgenic mice than
that in WT mice on day 2 (Fig. 2E,F). The index in HGF
transgenic mice was signi¢cantly decreased (HGF, 9.59P 5.3;
WT, 30.1P 16.2, P6 0.01). In all mice, the damage had re-
solved by day 7 (data not shown).
3.2. Expression of transgenes and endogeneous HGF, c-met and
MT in livers following CCl4 administration
High expression of each transgene was detected at each time
point in each transgenic liver (Fig. 3). In particular, higher
expression of each transgene was detected on day 1. Because
CCl4 up-regulates the endogeneous MT level in the liver sug-
gesting that CCl4 activates the MT promoter in their con-
structs [26], we investigated MT expression. However, MT
expression was not increased after injection of CCl4 (Fig. 3).
Endogeneous HGF expression increased in WT and NK2
transgenic mice but did not increase in HGF transgenic
mice on day 1. On the other hand, endogeneous c-met expres-
sion decreased in HGF transgenic mice but did not decrease
in WT and NK2 transgenic mice on days 1 and 2 (Fig. 3).
3.3. Hepatocyte proliferation after CCl4 administration
PCNA staining was performed to analyze hepatocyte pro-
liferation of each mouse on days 0 and 2 (Fig. 4). The labeling
index of NK2 transgenic hepatocytes was similar to that of
WT hepatocytes on day 0 (WT, 2.70P 2.18; NK2, 2.13P 1.80)
and day 2 (WT, 45.5 P 7.60; NK2, 45.5P 7.13) (Fig. 5). In
contrast, the labeling index of HGF transgenic hepatocytes
was signi¢cantly increased relative to that of WT on day 0
(WT, 2.70P 2.18; HGF, 9.70P 4.96, P6 0.01). Moreover, the
labeling index of HGF transgenic hepatocytes was signi¢-
cantly decreased relative to that of WT on day 2 (WT,
45.5P 7.60; HGF, 21.0P 5.46, P6 0.01) (Fig. 5).
4. Discussion
We investigated e¡ects of HGF and NK2 on CCl4-induced
acute liver injury using HGF and NK2 transgenic mice. Re-
portedly, intermittent injection of recombinant HGF and the
implantation of HGF-producing cells into the spleen protect
against CCl4-induced acute liver injury [4,8]. However, there
has been no report which describes continuous HGF over-
expression in vivo. We exploited HGF transgenic mice to
provide more direct evidence that HGF protects from CCl4-
induced acute liver injury in vivo. After CCl4 administration,
serum ALT levels in HGF transgenic mice were dramatically
lower than those in WT mice and the degree of the centrilob-
ular necrosis in HGF transgenic mice was remarkably reduced
relative to that in WT mice. These results indicate that HGF
overexpression protects hepatocytes from damage induced by
CCl4 administration in vivo. In contrast, serum ALT levels in
NK2 transgenic mice were signi¢cantly higher than those in
WT mice and the degree of the centrilobular necrosis in NK2
transgenic mice was more severe than that in WT mice after
CCl4 administration. These data indicate that NK2 overex-
pression antagonizes the protective e¡ect of endogeneous
Fig. 1. Serum ALT levels in WT, NK2 transgenic, and HGF trans-
genic mice on days 0, 1, 2, and 7. CCl4-induced acute liver injury
was inhibited in HGF transgenic mice but was stimulated in NK2
transgenic mice, as compared to WT mice (n=3^9 per group). The
P value is 6 0.01.
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HGF in terms of promoting liver injury induced by CCl4
administration in vivo. The hepatic expressions of transgene
transcripts were very high at each time point after CCl4 ad-
ministration. We previously checked the relative levels of NK2
and HGF proteins expressed in the transgenic mouse livers
and NK2 was present in a seven-fold molar excess relative to
HGF [23]. The expression of endogeneous HGF was increased
on day 1 but had returned to the initial level by day 2 in WT
mice. This result is consistent with the observation that the
plasma HGF level peaked at 24 h after CCl4 administration,
then decreased to the initial level at 72 h, in the rat [27]. On
day 1, although the expression of endogeneous HGF was
induced in NK2 transgenic mice, it was not induced in
HGF transgenic mice. This suggested that HGF overexpres-
sion inhibited CCl4-induced acute liver injury resulting in re-
duced expression of endogeneous HGF. The expression of
endogeneous c-met RNA in the livers of WT and NK2 trans-
genic mice was unchanged at each time point after CCl4 ad-
ministration. The expression in HGF transgenic mice was re-
duced on days 1 and 2, implying that marked overexpression
of HGF decreased c-met expression. In fact, the HGF in-
crease induced by CCl4 administration down-regulated c-Met
[28].
HGF is required for liver regeneration following necrosis
Fig. 3. RNA expressions of transgenic (Tg) HGF and NK2, and en-
dogeneous (E) HGF, c-met and MT in livers from WT, transgenic
mice on days 0, 1, 2, and 7. All transgene expressions were high at
each time point. After CCl4 administration, endogeneous HGF ex-
pression increased in WT and NK2 transgenic mice, and endogene-
ous c-met expression decreased in HGF transgenic mice, and endo-
geneous MT expression was unaltered in WT and transgenic mice.
Fig. 2. Histological ¢ndings in livers of WT mice (A and B), NK2 transgenic mice (C and D), and HGF transgenic mice (E and F) before
CCl4 administration (A, C, and E) and 2 days after CCl4 administration (B, D, and F). There are no necrotic areas in the livers, in any of the
groups, before CCl4 administration. On day 2, the degrees of centrilobular necrosis in NK2 transgenic mice are larger than that in WT mice,
but the necrosis in HGF transgenic mice is much less severe than that in WT mice. The arrows indicate centrilobular necrosis. Magni¢cation,
U100.
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induced by CCl4 administration [29] but the role of NK2 in
liver regeneration is not known. The PCNA labeling index of
HGF transgenic mouse livers is 3.6-fold higher than that of
WT mouse livers before CCl4 administration. On the other
hand, the index of NK2 transgenic mouse livers is the same
level as that of WT mouse livers before CCl4 administration.
These results are consistent with previous data using BrdU
incorporation to estimate hepatocyte proliferation in these
mice [23]. The index of HGF transgenic mouse livers is sig-
ni¢cantly smaller than that of WT mouse livers on day 2. This
result suggests that HGF protects hepatocytes from CCl4-in-
duced damage in vivo, because the proliferative response takes
place in severely damaged liver tissue [30]. When NK2 trans-
genic mice were treated with ZnSO4 in water, a small reduc-
tion in liver size was observed [23]. This result indicated that
NK2 was able to inhibit endogeneous HGF-mediated hepato-
cyte proliferation in vivo. We examined whether NK2 over-
expression inhibits the proliferative e¡ect of endogeneous
HGF induced by CCl4 administration. There was no di¡er-
ence in cell proliferation between NK2 transgenic mice and
WT mice on day 2. This result suggests that the hepatocyte
proliferative response to CCl4 may not require HGF alone
and another factor may play a role in liver regeneration fol-
lowing necrosis induced by CCl4 administration.
In conclusion, this study shows that overexpression of HGF
prevents CCl4-induced acute liver injury, while that of NK2
stimulates in vivo. This provides direct evidence that HGF
exerts a protective e¡ect and NK2 behaves as an antagonist
of HGF in respect of the protective e¡ect on liver injury.
However, overexpression of NK2 did not inhibit hepatocyte
proliferation after liver damage. Further studies are required
to determine the function of NK2 in vivo.
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